{"public_id":"co_f3e347f3a88a8a552b92ee1e5a65d8e1","status":"active","merged_into_public_id":null,"resolved_public_id":"co_f3e347f3a88a8a552b92ee1e5a65d8e1","name":"salvage HDCT/ASCT","description":"Salvage high dose chemotherapy and autologous stem cell transplantation in the ReLApsE trial arm B.","aliases":["salvage HDCT","salvage ASCT"],"types":["treatment arm","intervention"],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":2,"verifier_classes":["system"],"verifier_class_counts":{"system":2,"user_agent":0},"verdict_counts":{"approve":1,"reject":1},"verifier_state":"system_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":80715406,"title":"Subgroup Analyses of the Randomized GMMG Phase III Multicenter Trial Relapse Suggest Survival Benefit of Salvage Autologous Transplant Primarily in Low Risk Multiple Myeloma","citation_count":13,"url":"https://sah.borca.ai/papers/80715406"}],"claims":[{"public_id":"cl_2ffdd26facdf2db30170824b29776703","text":"Patients with R-ISS I had significantly superior OS in arm B (HR 0.08; p=0.02), whereas no significant OS difference was seen in patients with R-ISS II (HR 0.72, p=0.42) or R-ISS III (HR 0.65, p=0.6).","corpus_id":80715406,"url":"https://sah.borca.ai/claims/cl_2ffdd26facdf2db30170824b29776703"},{"public_id":"cl_44c883846bb768d87e247dc3bec28044","text":"Multivariate landmark analyses showed significant associations of the salvage HDCT/ASCT arm with superior PFS (HR 0.6; p=0.01) and OS (HR 0.39; p=0.006).","corpus_id":80715406,"url":"https://sah.borca.ai/claims/cl_44c883846bb768d87e247dc3bec28044"},{"public_id":"cl_6393f69944fdfa984f811dca2a0a0b82","text":"Patients with front-line HDCT/ASCT treated in arm B had significant PFS benefit (HR 0.68, p=0.03) and OS benefit (HR 0.43, p=0.009), whereas patients without front-line HDCT/ASCT had inferior survival in arm B (PFS: HR 4.35, p=0.08; OS: HR 19.83, p=0.0078).","corpus_id":80715406,"url":"https://sah.borca.ai/claims/cl_6393f69944fdfa984f811dca2a0a0b82"},{"public_id":"cl_73e69d0ad343027dd564e11aac884b40","text":"Landmark analyses from salvage HDCT showed a survival benefit in patients actually undergoing salvage HDCT/ASCT, with median PFS 23.3 vs. 20.1 months (HR 0.74; p=0.09) and median OS not reached vs. 57 months (HR 0.56; p=0.046) favoring the salvage HDCT/ASCT arm.","corpus_id":80715406,"url":"https://sah.borca.ai/claims/cl_73e69d0ad343027dd564e11aac884b40"},{"public_id":"cl_eee68f4ee8c67b2041b0a3762d5ffb8b","text":"Patients with low risk cytogenetics had significantly superior OS in arm B (HR 0.21; p=0.01), whereas patients with high risk cytogenetics had no significant OS difference (HR 0.82, p=0.67).","corpus_id":80715406,"url":"https://sah.borca.ai/claims/cl_eee68f4ee8c67b2041b0a3762d5ffb8b"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_f3e347f3a88a8a552b92ee1e5a65d8e1","url":"https://sah.borca.ai/concepts/co_f3e347f3a88a8a552b92ee1e5a65d8e1"}